📊 NAUT Key Takeaways
Is Nautilus Biotechnology, Inc. (NAUT) a Good Investment?
Nautilus Biotechnology is a pre-revenue/early-stage company with no reported revenue, significant operating losses (-$1.8M), and substantial net losses (-$14.7M). Operating cash burn of -$13.1M annually against only $14.6M in cash reserves provides limited runway (~1.3 years) with no clear path to profitability. While the balance sheet is debt-free and initially appears strong, the fundamental business model has not demonstrated commercial viability.
Nautilus remains effectively pre-revenue with substantial net losses and deeply negative free cash flow, indicating unclear line-of-sight to self-sustaining operations. While the balance sheet shows high liquidity and no debt, cash burn is significant and raises financing risk absent near-term commercialization traction.
Nautilus Biotechnology, Inc. Key Strengths (NAUT)
- Strong balance sheet with $144.4M stockholders' equity and minimal liabilities
- Excellent liquidity position (11.85x current ratio, 11.81x quick ratio) providing near-term operational flexibility
- Zero long-term debt and fully debt-free capital structure
- Modest improvement in EPS (-0.12) showing 16.1% YoY enhancement despite losses
- Operating in high-potential laboratory analytical instruments sector (SIC 3826)
- Very strong liquidity (13.33x current ratio)
- Zero leverage (0.00x D/E) provides flexibility
- Low capex intensity supports capital-light model
NAUT Stock Risks: Nautilus Biotechnology, Inc. Investment Risks
- No revenue reported - inability to assess commercial viability, product-market fit, or business model sustainability
- Severe cash burn of -$13.1M annually from operations with only ~1.3 years of cash runway remaining
- Persistent and substantial operating losses (-$1.8M) and net losses (-$14.7M) with no profitability trajectory visible
- Negative returns on equity (-10.2%) and assets (-8.3%) indicating value destruction for shareholders
- Pre-revenue or very early-stage commercialization status with unproven ability to generate revenue at scale
- Prolonged pre-revenue status and commercialization uncertainty
- High cash burn and negative FCF heighten financing/dilution risk
- Sustained negative ROE/ROA signal poor capital efficiency
Key Metrics to Watch
- Revenue generation and timing of commercial product launches
- Quarterly cash burn rate and cash runway extension milestones
- Progress toward gross margin profitability and operating margin breakeven
- Customer acquisition, pipeline development, and proof-of-concept validations
- Total cash and marketable securities
- Operating cash flow (quarterly burn)
Nautilus Biotechnology, Inc. (NAUT) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 11.85x current ratio provides a solid financial cushion.
NAUT Profit Margin, ROE & Profitability Analysis
NAUT vs Industrial Sector: How Nautilus Biotechnology, Inc. Compares
How Nautilus Biotechnology, Inc. compares to Industrial sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Nautilus Biotechnology, Inc. Stock Overvalued? NAUT Valuation Analysis 2026
Based on fundamental analysis, Nautilus Biotechnology, Inc. has mixed fundamental signals relative to the Industrial sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Nautilus Biotechnology, Inc. Balance Sheet: NAUT Debt, Cash & Liquidity
NAUT Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Nautilus Biotechnology, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-0.56 indicates the company is currently unprofitable.
NAUT Revenue Growth, EPS Growth & YoY Performance
Nautilus Biotechnology, Inc. Dividends, Buybacks & Capital Allocation
NAUT SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Nautilus Biotechnology, Inc. (CIK: 0001808805)
📋 Recent SEC Filings
❓ Frequently Asked Questions about NAUT
What is the AI rating for NAUT?
Nautilus Biotechnology, Inc. (NAUT) has a Combined AI Grade of C from Claude (D) and ChatGPT (C) with 78% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are NAUT's key strengths?
Claude: Strong balance sheet with $144.4M stockholders' equity and minimal liabilities. Excellent liquidity position (11.85x current ratio, 11.81x quick ratio) providing near-term operational flexibility. ChatGPT: Very strong liquidity (13.33x current ratio). Zero leverage (0.00x D/E) provides flexibility.
What are the risks of investing in NAUT?
Claude: No revenue reported - inability to assess commercial viability, product-market fit, or business model sustainability. Severe cash burn of -$13.1M annually from operations with only ~1.3 years of cash runway remaining. ChatGPT: Prolonged pre-revenue status and commercialization uncertainty. High cash burn and negative FCF heighten financing/dilution risk.
What is NAUT's revenue and growth?
Nautilus Biotechnology, Inc. reported revenue of N/A.
Does NAUT pay dividends?
Nautilus Biotechnology, Inc. does not currently pay dividends.
Where can I find NAUT SEC filings?
Official SEC filings for Nautilus Biotechnology, Inc. (CIK: 0001808805) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is NAUT's EPS?
Nautilus Biotechnology, Inc. has a diluted EPS of $-0.12.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is NAUT's fundamental grade?
Based on our AI fundamental analysis in June 2026, Nautilus Biotechnology, Inc. has a C grade with 78% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is NAUT stock overvalued or undervalued?
Valuation metrics for NAUT: ROE of -10.2% (sector avg: 15%), net margin of N/A (sector avg: 10%). Compare these metrics with sector averages to assess valuation.
What is NAUT's AI grade for 2026?
Our dual AI analysis gives Nautilus Biotechnology, Inc. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is NAUT's free cash flow?
Nautilus Biotechnology, Inc.'s operating cash flow is $-13.1M, with capital expenditures of $510.0K.
How does NAUT compare to other Industrial stocks?
Vs Industrial sector averages: Net margin N/A (avg: 10%), ROE -10.2% (avg: 15%), current ratio 11.85 (avg: 1.8).